The US FDA has approved orforglipron, a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. Clinical evidence In a clinical trial, orforglipron demonstrated superior efficacy to placebo in reducing body weight over 72 weeks, with a favorable safety profile in adults with obesity or overweight, including those with and without type 2 diabetes. Dosage and administration Available in tablet form Take orforglipron orally once daily, with or without food Swallow tablets whole.
Do not break, crush, or chew Do not take more than one tablet per day Starting dosage is 0.8 mg once daily. After at least 30 days, increase dosage to 2.5 mg once daily After at…
